nach oben

Journal of Neuro-Oncology

Erschienen in:

01.03.2009 | Topic review

Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas

verfasst von: Chrissa Sioka, Athanassios P. Kyritsis

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Meningioma is a common intracranial tumor, originating from the meninges of the skull or spinal canal. Most meningiomas are benign tumors, however atypical or anaplastic tumors can be found in 6% of cases. Patients with asymptomatic small benign meningiomas can be followed without therapy, but in symptomatic patients complete surgical resection should be performed. For recurrent previously resected tumors re-resection is recommended followed by radiotherapy in selected cases. Antiprogesterone treatment can also be considered in recurrent benign meningiomas. Immunotherapy with interferon-alpha and chemotherapy should be reserved for all cases of recurrent meningiomas (benign, atypical, and malignant) when all the standard therapies have failed or contraindicated.

Kaba SE, Kyritsis AP (2006) Atypical and malignant meningiomas. In: Raghavan D, Brecher ML, Johnson DH, Metopol NJ, Moots PL, Rose P (eds) Textbook of uncommon cancer. John Wiley & Sons, West Sussex, England, pp. 303–314

Kyritsis AP (1996) Chemotherapy for meningiomas. J Neurooncol 29:269–272. doi:10.1007/BF00165657 PubMedCrossRef

Andersson U, Malmer B, Bergenheim AT, Brannstrom T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21–27PubMed

Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y (2007) A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene. Gan To Kagaku Ryoho 34:265–268PubMed

Buccoliero AM, Castiglione F, Degl’Innocenti DR, Arganini L, Taddei A, Ammannati F, Mennonna P, Taddei GL (2007) Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry. Appl Immunohistochem Mol Morphol 15:187–192. doi:10.1097/01.pai.0000201807.58801.fc PubMedCrossRef

Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 103(3):508–517PubMed

Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2007) Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109:588–597. doi:10.1002/cncr.22441 PubMedCrossRef

Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS (2002) Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 56:133–142. doi:10.1023/A:1014588214966 PubMedCrossRef

Braun B, Lange M, Oeckler R, Mueller MM (2004) Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 68:131–140. doi:10.1023/B:NEON.0000027751.87894.f0 PubMedCrossRef

10.

Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD (2008) Evaluation of meningioma aggressiveness by (99 m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg 110:645–648. doi:10.1016/j.clineuro.2008.03.016 PubMedCrossRef

11.

Alexiou GA, Tsiouris S, Goussia A, Polyzoidis KS, Fotopoulos AD, Kyritsis AP (2008) (99 m)Tc-Tetrofosmin SPECT for the assessment of meningioma malignancy. J Clin Neurosci 15:721–722. doi:10.1016/j.jocn.2007.08.031 PubMedCrossRef

12.

Chamberlain MC, Glantz MJ (2005) Cerebrospinal fluid-disseminated meningioma. Cancer 103:1427–1430. doi:10.1002/cncr.20926 PubMedCrossRef

13.

Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840–844PubMed

14.

Newton HB, Slivka MA, Stevens C (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165–170. doi:10.1023/A:1026770624783 PubMedCrossRef

15.

Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18:495–499PubMedCrossRef

16.

Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341–346PubMed

17.

Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221–226. doi:10.1023/B:NEON.0000021827.85754.8e PubMedCrossRef

18.

Weston GJ, Martin AJ, Mufti GJ, Strong AJ, Gleeson MJ (2006) Hydroxyurea treatment of meningiomas: a pilot study. Skull Base 16:157–160. doi:10.1055/s-2006-949518 PubMedCrossRef

19.

Fuentes S, Chinot O, Dufour H, Paz-Paredes A, Metellus P, Barrie-Attarian M, Grisoli F (2004). Hydroxyurea treatment for unresectable meningioma Neurochirurgie 50:461–467. doi:10.1016/S0028-3770(04)98326-9

20.

Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157–165. doi:10.1007/s11060-004-2337-3 PubMedCrossRef

21.

Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC, Hofman FM, Schonthal AH, Chen TC (2007) Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg 106:455–462. doi:10.3171/jns.2007.106.3.455 PubMedCrossRef

22.

Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78:271–276. doi:10.1007/s11060-005-9093-x PubMedCrossRef

23.

Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865–1874PubMed

24.

Prat R, Banzo J, Diaz FJ (1997).Somatostatin receptors in meningioma: diagnostic and therapeutic value. Rev Neurol 25:2002–2005

25.

Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66:155–166. doi:10.1023/B:NEON.0000013498.19981.55 PubMedCrossRef

26.

Kunert-Radek J, Stepien H, Radek A, Pawlikowski M (1987) Somatostatin suppression of meningioma cell proliferation in vitro. Acta Neurol Scand 75:434–436PubMed

27.

Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJ, Lamberts SW, Reubi JC (1992) Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 74:543–547. doi:10.1210/jc.74.3.543 PubMedCrossRef

28.

Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969–973. doi:10.1212/01.wnl.0000271382.62776.b7 PubMedCrossRef

29.

Koper JW, Zwarthoff EC, Hagemeijer A, Braakman R, Avezaat CJ, Bergstrom M, Lamberts SW (1991) Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 27:416–419PubMed

30.

Wober-Bingol C, Wober C, Marosi C, Prayer D (1995) Interferon-alfa-2b for meningioma. Lancet 345:331. doi:10.1016/S0140-6736(95)90326-7 PubMedCrossRef

31.

Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, Yung WK (1997) The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:271–275. doi:10.1097/00006123-199702000-00007 PubMedCrossRef

32.

Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B (2001) Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 7:2269–2276PubMed

33.

Huisman TW, Tanghe HL, Koper JW, Reubi JC, Foekens JA, Avezaat CJ, Braakman R, Lamberts SW (1991) Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics. Eur J Cancer 27:1453–1457PubMed

34.

Grunberg SM (1994) Role of antiprogestational therapy for meningiomas. Hum Reprod 9(suppl 1):202–207PubMed

35.

Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861–866PubMedCrossRef

36.

Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H (1992) Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55:486–490PubMedCrossRef

37.

Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24:727–733. doi:10.1080/07357900601062339 PubMedCrossRef

38.

Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15:75–77. doi:10.1007/BF01050266 PubMedCrossRef

39.

Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Masuo O, Naito Y (2000) Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report. J Neurosurg 93:132–135PubMed

40.

Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD (1995) In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 36:365–373. doi:10.1097/00006123-199502000-00017 PubMedCrossRef

41.

Jensen RL, Petr M, Wurster RD (2000) Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery 46:692–702. doi:10.1097/00006123-200003000-00032 PubMedCrossRef

42.

Ragel BT, Gillespie DL, Kushnir V, Polevaya N, Kelly D, Jensen RL (2006) Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery 59:1109–1120. doi:10.1227/01.NEU.0000232864.73007.38 PubMedCrossRef

43.

Ragel BT, Couldwell WT, Wurster RD, Jensen RL (2007) Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus 23(4):E10PubMedCrossRef

Titel: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas
verfasst von: Chrissa Sioka
Athanassios P. Kyritsis
Publikationsdatum: 01.03.2009
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9734-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Fatigue in low-grade glioma

Is biopsy needed to guide management for all patients with presumed intracranial ectopic germinomas

Expression of HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein in multiple schwannomas of the conus medullaris

Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)